MediRad

Call: NFRP-2016-2017

Topic: NFRP-9; Type of action: RIA (Research and Innovation action)

Proposal number: 755523

PARCERIA:

EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG Austria

FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA Spain

UNIVERSITE PARIS DESCARTES France

PANEPISTIMIO KRITIS Greece

THE ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST United Kingdom

ACADEMISCH ZIEKENHUIS GRONINGEN Netherlands

INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE France

OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG Germany

INSTITUTO POLITECNICO DE COIMBRA Portugal

VASTRA GOTALANDS LANS LANDSTING Sweden

UNIVERSITAT POLITECNICA DE CATALUNYA Spain

INSTYTUT MEDYCYNY PRACY IMIENIA PROF. DRA MED. JERZEGO NOFERA W LODZI Poland

B-COM France

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ Germany

UNIVERSITE DE GENEVE Switzerland

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH Germany

STUDIECENTRUM VOOR KERNENERGIE/CENTRE D’ETUDE DE L’ENERGIE NUCLÉAIRE Belgium

UNIVERSITEIT GENT Belgium

UNIVERSITAETSKLINIKUM WUERZBURG – KLINIKUM DER BAYERISCHEN JULIUS MAXIMILIANSUNIVERSITAT Germany

PHILIPPS UNIVERSITAET MARBURG Germany

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France

INVESTIGADOR RESPONSÁVEL IPC:

GRACIANO NOBRE PAULO (ESTeSC)

FINANCIAMENTO:

Investimento Elegível: 10.000.000,00  €

Apoio da União Europeia:

Incentivo Não Reembolsável (85,5%)

Comparticipação dos promotores (14,5%)

Investimento elegível IPC: 188.800,00 €

DESCRIÇÃO SUMÁRIA:

MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection (RP) in the medical field and thereby addresses the need to understand and evaluate the health effects of low dose ionising radiation exposure from diagnostic and therapeutic imaging and from off-target effects in radiotherapy (RT). MEDIRAD will pursue 3 major operational objectives:

First, it will improve organ dose estimation and registration to inform clinical practice, optimise doses, set recommendations and provide adequate dosimetry for clinical epidemiological studies of effects of medical radiation;

Second, it aims to evaluate and understand the effects of medical exposures, focusing on the two major endpoints of public health relevance: cardiovascular effects of low to moderate doses of radiation from RT in breast cancer treatment including understanding of mechanisms; and long-term effects on cancer risk of low doses from CT in children.

Third, it will develop science-based consensus policy recommendations for the effective protection of patients, workers and the general public.

Within the 4-year project a multi-disciplinary consortium will, in close interaction with European medical associations, MELODI and EURADOS:

(1), develop a tool to determine image quality to maximise optimisation of RP in medical imaging;

(2) improve and develop new individual organ/anatomical structure dosimetry from chest CT, I131 administration, fluoroscopy-guided procedures, hybrid imaging, and RT for breast cancer and interlinks with image quality measures;

(3) conduct epidemiological studies of consequences of RT and CT;

(4) identify potential novel imaging and circulating biomarkers and mechanisms of radiation effects;

(5) develop innovative risk models;

(6) develop and implement for the first time a European repository of patient dose and imaging data;

(7) develop science-based recommendations;

(8) introduce novel approaches to bring together the nuclear and medical sectors.